EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transcriptomic Profiling Pre- and Post-Dupilumab Treatment in Atopic Dermatitis Using Minimally Invasive Microneedle Sampling: A Pilot Study

Seo Hyeong Kim, Narang Hong, Ji Hye Kim, Ho Eun Gwag, Ji Tae Kim, Do Hyeon Jeong, Jiyoung Ahn, Kwang Hoon Lee

International Journal of Molecular Sciences · 12.11.2026 · 27 (22) · 10150

DOI: 10.3390/ijms272210150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.11.2026. Verfasst von Seo Hyeong Kim und 7 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individual differences in dupilumab treatment response remain an unmet need. This pilot study aimed to explore transcriptomic changes and candidate molecular signals that may reflect disease activity and treatment response by analyzing gene expression changes in patients with atopic dermatitis (AD) using a minimally invasive microneedle-based skin sampling method (MISSM). Lesional and non-lesional skin samples were collected from six patients with moderate to severe AD before and 16 weeks after dupilumab treatment, and only samples exceeding a predefined complementary RNA (cRNA) yield threshold following pico-scale RNA amplification were analyzed by microarray. Transcriptome profiling identified several genes, including immunoglobulin variable-region and T-cell receptor genes, that showed correlation trends with clinical improvement (change in Eczema Area and Severity Index, ΔEASI) and significant changes after treatment in the responder group. Baseline expression of other immune-related genes, such as chemokines and immunoglobulins, differed between responders and non-responders. As these findings were derived from a small, non-independent cohort, they should be regarded as exploratory signals rather than validated biomarkers. We also demonstrated that MISSM is a feasible platform for multi-layered analysis of molecular changes in AD, supporting its potential utility for longitudinal treatment response monitoring and molecular profiling in chronic inflammatory skin disease.

Zitieren

APA

Kim, S. H., Hong, N., Kim, J. H., Gwag, H. E., Kim, J. T., Jeong, D. H., Ahn, J., & Lee, K. H. (2026). Transcriptomic Profiling Pre- and Post-Dupilumab Treatment in Atopic Dermatitis Using Minimally Invasive Microneedle Sampling: A Pilot Study. International Journal of Molecular Sciences, 27(22), 10150. https://doi.org/10.3390/ijms272210150

Vancouver

Kim SH, Hong N, Kim JH, Gwag HE, Kim JT, Jeong DH, et al. Transcriptomic Profiling Pre- and Post-Dupilumab Treatment in Atopic Dermatitis Using Minimally Invasive Microneedle Sampling: A Pilot Study. International Journal of Molecular Sciences. 2026;27(22):10150. doi:10.3390/ijms272210150

BibTeX
@article{Kim2026,
  author = {Kim, Seo Hyeong and Hong, Narang and Kim, Ji Hye and Gwag, Ho Eun and Kim, Ji Tae and Jeong, Do Hyeon and Ahn, Jiyoung and Lee, Kwang Hoon},
  title = {Transcriptomic Profiling Pre- and Post-Dupilumab Treatment in Atopic Dermatitis Using Minimally Invasive Microneedle Sampling: A Pilot Study},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10150},
  doi = {10.3390/ijms272210150}
}
Kostenlos starten →